Bio-Techne price target lowered to $72 from $79 at RBC Capital

RBC Capital analyst Conor McNamara lowered the firm’s price target on Bio-Techne (TECH) to $72 from $79 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q1 results in the Life Science Tools and Diagnostics sector. The firm anticipates another optimistic tone from the sector’s management teams while also updating its models to reflect a “more realistic” outlook on where FY25 guidance for most of these companies should go in light of NIH grant funding cuts, tariffs, and a pending trade war with China that is already having an impact, the analyst tells investors in a research note.